ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoimmune diseases"

  • Abstract Number: 2147 • ACR Convergence 2023

    Safety and Effectiveness in Cycling Between Non-Selective and Selective JAKi in a Multi-Center Registry of Rheumatoid Arthritis in the Middle East

    Rajaie Namas1, Jawahir Alameri2, Sarah Al Qassimi2, Ha-Neul Yu3, Mohamed Elarabi2, Hani Shatnawi4, Lara Memisoglu2, Ahlam Al Marzooqi5, Asia Mubashir2 and Eduardo Mysler6, 1Medical Subspecialties Institute, Division of Rheumatology, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, 2Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, 3New York University Abu Dhabi, Abu Dhabi, United Arab Emirates, 4Princess Basma Teaching Hospital, Amman, Jordan, 5Al Qassimi Hospital, Sharjah, United Arab Emirates, 6Organización Medica de Investigación, Buenos Aires, Argentina

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease. Strategies for addressing treatment failure with TNF inhibitors according to the recent EULAR recommendations include…
  • Abstract Number: 2442 • ACR Convergence 2023

    Neutrophils Induce Contact-Dependent Expansion of Arthritogenic Th17 Cells and Are Necessary for Disease in Experimental Ankylosing Spondylitis

    Hillary Struthers1, Emily Vance1, Kofi Asare-Konadu1, Holly Rosenzweig2 and Ruth Napier1, 1Oregon Health & Science University, Portland, OR, 2VA Portland Healthcare System, Portland, OR

    Background/Purpose: Ankylosing spondylitis (AS) patients have irregular neutrophil responses, as indicated clinically by neutrophilia and increased neutrophil to lymphocyte ratios that positively associate with disease…
  • Abstract Number: 2574 • ACR Convergence 2023

    Are Patients Classified as IPAF More Likely to Also Meet SLE Criteria by 2019 EULAR/ACR Than by SLICC?: An Abstract

    Gabriela Martinez Zayas1, David Karp1 and Elena Joerns2, 1UT Southwestern Medical Center, Dallas, TX, 2University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) is a research classification proposed by the European Respiratory Society and American Thoracic Society Task Force for those…
  • Abstract Number: 0017 • ACR Convergence 2023

    Xist Ribonucleoproteins Promote Female Sex-biased Autoimmunity

    Diana Dou1, Yanding Zhao1, Julia Belk1, Yang Zhao1, Kerriann Casey2, Derek Chen1, Rui Li1, Bingfei Yu1, Suhas Srinivasan1, Brian Abe1, Katerina Kraft1, Ceke Hellström3, Ronald Sjöberg4, Sarah Chang5, Allan Feng5, Daniel Goldman6, Ami Shah7, Michelle Petri6, Lorinda Chung8, David Fiorentino9, Emma Lundberg10, Anton Wutz11, Paul Utz5 and Howard Chang1, 1Center for Personal Dynamic Regulomes and Program in Epithelial Biology, Department of Dermatology, Stanford University School of Medicine, Stanford, CA, 2Department of Comparative Medicine, Stanford University, Stanford, CA, 3Autoimmunity and Serology Profiling, Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden, 4Department of Protein Science, SciLifelab, KTH Royal Institute of Technology, Stockholm, Sweden, 5Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 6Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 7Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, 8Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, 9Department of Dermatology, Stanford University School of Medicine, Menlo Park, CA, 10Departments of Bioengineering and Pathology, Stanford University, Stanford, CA, 11Department of Biology, Institute of Molecular Health Sciences, Swiss Federal Institute of Technology, ETH Hönggerberg, Zurich, Switzerland

    Background/Purpose: Autoimmune diseases disproportionately affect females more than males. The XX sex chromosome complement is strongly associated with susceptibility to autoimmunity. Xist long noncoding RNA…
  • Abstract Number: 0089 • ACR Convergence 2023

    Pre-Clinical Characterization of MTX-101, a Novel Bispecific CD8 Treg Modulator with the Potential to Restore CD8 Treg Functions in Patients with Rheumatological Autoimmune Diseases

    Daniel Patton, Meghan Maurer, Nadine Morgan, Minh Pham, Daniel Boster, Justin Huard, Cathy Tan, Rachael Fasnacht, Monica Childs, Gleda Hermansky, Alex Chen, Susan Julien, Jennifer Gardell, Cathy McMahan, Courtney Crane and Kristine Swiderek, Mozart Therapeutics, Seattle, WA

    Background/Purpose: In healthy individuals, CD8 Treg activation leads to selective elimination of aberrantly activated self-reactive CD4 T cells to maintain immune balance. The CD8 Treg…
  • Abstract Number: 0220 • ACR Convergence 2023

    Paxlovid (Nirmatrelvir Plus Ritonavir) in Patients with Underlying Rheumatological Diseases, in Preventing COVID-19 Related Hospitalization and Death

    Faiza Javed, Tony Mangino and Paramarajan Piranavan, University of Kentucky College of Medicine, Lexington, KY

    Background/Purpose: The benefits of antiviral therapy in the COVID-19 patients with underlying rheumatic disease with or without immunosuppression are not entirely clear. The goal of…
  • Abstract Number: 0339 • ACR Convergence 2023

    Longitudinal Glucocorticoid Toxicity in Rheumatic Disease Patients (LONG-TOX) and Associations with Quality of Life and Healthcare Resource Utilization: Interim Analysis from a Prospective Cohort

    Naomi Patel1, Aubree McMahon1, Grace McMahon1, Sebastian Perez-Espina1, Isha Jha1, Adam Jarvie1 and John Stone2, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA

    Background/Purpose: Glucocorticoids (GCs) continue to be the cornerstone of therapy for many rheumatic diseases, though long-term exposure to GCs has been linked to dozens of…
  • Abstract Number: 0583 • ACR Convergence 2023

    Therapeutic Potential of Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, for the Treatment of Refractory Autoimmune Disease Patients

    Racquel Domingo-Gonzalez1, Isabelle Baribaud2, Miho Oyasu1, Sivani Pandey1, Maya Leabman1, Genevive Hernandez1, Albert Candia1, Stephen Carroll1, Bruce Keyt1, Maya Kotturi1, Carrie Brodmerkel2 and Mary Beth Harler2, 1IGM Biosciences, Inc., Mountain View, CA, 2IGM Biosciences, Inc., Doylestown, PA

    Background/Purpose: B cell depletion therapy (BCDT) with conventional IgG antibodies (e.g.rituximab) has been used to treat autoimmune (AI) disease for several decades. However, many patients…
  • Abstract Number: 0825 • ACR Convergence 2023

    A Revised Outcome Measure for Dermatomyositis Clinical Trials: The Dermatomyositis Outcomes for Muscle and Skin (DMOMS)

    Rachita Pandya1, Joshua Dan2, Julianne Kleitsch1, Darosa Lim3, Barbara White4 and Victoria P. Werth5, 1Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2Icahn School of Medicine at Mount Sinai, New York, NY, 3University of Pennsylvania, Philadelphia, PA, 4SFJ Pharmaceuticals, Towson, MD, 5University of Pennsylvania, Wynnewood, PA

    Background/Purpose: Current clinical trials in dermatomyositis (DM) are largely focused on muscle improvement, and use the Total Improvement Score (TIS) as the primary efficacy measure.…
  • Abstract Number: 1016 • ACR Convergence 2023

    Cost-related Medication Burden for Patients with and Without Systemic Autoimmune Rheumatic Diseases

    Jeong Yee1, Candace Feldman1, Emily G. Oakes1, Jack Ellrodt1, May Choi2, Elizabeth Karlson1 and Karen Costenbader3, 1Brigham and Women's Hospital, Boston, MA, 2University of Calgary, Calgary, AB, Canada, 3Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Medication nonadherence is a challenging issue in the management of systemic autoimmune rheumatic diseases (SARDs), leading to poor clinical outcomes. Although it is complex…
  • Abstract Number: 1143 • ACR Convergence 2023

    Nationwide Analysis of Adult-Onset Still’s Disease with and Without Hemophagocytic Lymphohistiocytosis

    Faria Sami1, Michael Manansala2, Shilpa Arora1 and Augustine Manadan2, 1John H. Stroger Jr. Hospital of Cook County, Chicago, IL, 2Rush University Medical Center, Chicago, IL

    Background/Purpose: Adult-Onset Still's Disease (AOSD) commonly manifests with fever, arthritis, rash, liver dysfunction, lymphadenopathy, and hematologic abnormalities. AOSD is also associated with Hemophagocytic Lymphohistiocytosis (HLH).…
  • Abstract Number: 1414 • ACR Convergence 2023

    Effects of Apremilast on Changes in Cardiometabolic Parameters by Diabetes and Obesity Status in Patients with Psoriatic Arthritis

    Philip J. Mease1, Dafna Gladman2, Iain McInnes3, Sue Cheng4, Stephen Colgan5, Yuri Klyachkin6, Lichen Teng7 and Nehal Mehta8, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, 2Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, 3University of Glasgow, Glasgow, United Kingdom, 4Amgen, Inc., Bradenton, FL, 5Amgen, Inc., Halton Hills, ON, Canada, 6Amgen, Inc., Lexington, KY, 7Amgen, Inc., Thousand Oaks, CA, 8George Washington University School of Medicine, Washington, DC

    Background/Purpose: The prevalence of cardiometabolic diseases including obesity and diabetes is higher in patients with psoriatic arthritis (PsA) than those without PsA. Apremilast (APR) is…
  • Abstract Number: 1634 • ACR Convergence 2023

    Iscalimab (CFZ533) in Patients with Sjögren’s Disease: Week 24 Efficacy and Safety Results of a Randomized, Placebo-controlled, Phase 2b Dose-ranging Study

    Benjamin A Fisher1, Xavier Mariette2, Athena S Papas3, Thomas Grader-Beck4, Hendrika Bootsma5, Wan-Fai Ng6, Paul Van Daele7, Stephanie Finzel8, Sergio Elgueta9, Josef Hermann10, Sara McCoy11, Arthur Bookman12, Monika Sopala13, Wen-Lin Luo14, Cornelia Scheurer13 and Wolfgang Hueber13, 1University of Birmingham, Birmingham, United Kingdom, 2Université Paris-Saclay, Le Kremlin-Bicêtre, France, 3Division of Oral Medicine, Tufts School of Dental Medicine, Boston, MA, 4Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, 5Department of Rheumatology, University Medical Centre Groningen, Groningen, Netherlands, 6NIHR Newcastle Clinical Research Facility, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 7Department of internal medicine, Erasmus MC, Rotterdam, Netherlands, 8Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany, 9Clinical Research Chile SpA, Biomedical Research Centre, Valdivia, Chile, 10Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University Graz, Graz, Austria, 11University of Wisconsin School of Medicine and Public Health, Middleton, WI, 12Toronto Western Hospital, Toronto, ON, Canada, 13Novartis Pharma AG, Basel, Switzerland, 14Novartis Pharmaceuticals Corporation, East Hanover, NJ

    Background/Purpose: Sjögren's disease (SjD) is an autoimmune disease affecting secretory glands and other organs with no approved systemic treatments. Iscalimab (CFZ533) is a mAb directed…
  • Abstract Number: 1801 • ACR Convergence 2023

    Tixagevimab/Cilgavimab for the Prevention of COVID-19 in Vaccine-refractory Patients with Autoimmune Diseases: A Prospective Cohort Study

    Ioanna Minopoulou1, Koray Tascilar2, Giulia Corte1, Melek Yalcin Mutlu1, Katja Schmidt2, Daniela Bohr1, Fabian Hartmann2, Bernhard Manger2, Arnd Kleyer3, David Simon1, Thomas Harrer2, Georg Schett4 and Filippo Fagni1, 1Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology / Deutsches Zentrum Immuntherapie, Erlangen, Germany, 2Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, 3University Hospital Erlangen, Erlangen, Germany, 4Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

    Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) and particularly those treated with B-cell-depleting agents frequently fail to develop humoral responses to SARS-CoV-2 vaccinations and have…
  • Abstract Number: 1937 • ACR Convergence 2023

    Efficacy of Different Treatment Approaches for Cardiac Sarcoidosis

    Frank Cai1, Anisha Paulson1, Amy Wozniak2, Emily Gilbert2 and Rochella Ostrowski2, 1Loyola University Medical Center, Oak Park, IL, 2Loyola University Medical Center, Maywood, IL

    Background/Purpose: There is currently a lack of a consensus standardized guideline for the treatment of cardiac sarcoidosis (CS) because of its rarity, heterogeneity of disease…
  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • …
  • 80
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology